We are live on ! Find out more
DRMA icon

Dermata Therapeutics
DRMA

8 hedge funds and large institutions have $561K invested in Dermata Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

813% more capital invested

Capital invested by funds: $61.5K → $561K (+$500K)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

33% more funds holding

Funds holding: 6 → 8 (+2)

0.73% more ownership

Funds ownership: 0.22% → 0.95% (+0.73%)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$472K
2
UBS Group
UBS Group
Switzerland
+$69.4K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$25.1K
4
Jones Financial Companies
Jones Financial Companies
Missouri
+$14.8K
5
TRCT
Tower Research Capital (TRC)
New York
+$504

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$61

DRMA Hedge Fund Activity: Q1 2025 in Review

8 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q1 2025, worth a combined $561K — up 813% from $61.5K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new DRMA positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, adding an estimated $472K. The largest seller was Wells Fargo, cutting an estimated $61.

  • 8 institutional investors held Dermata Therapeutics (DRMA) as of Q1 2025, up from 6 in Q4 2024.
  • Funds reported $561K of Dermata Therapeutics stock for Q1 2025, up 813% quarter-over-quarter.
  • 2 funds opened new Dermata Therapeutics positions in Q1 2025 and 0 closed out, a net change of +2 holders.
  • The largest Dermata Therapeutics buyer in Q1 2025 was Armistice Capital, an estimated $472K added.
  • The largest Dermata Therapeutics seller in Q1 2025 was Wells Fargo, an estimated $61 sold.

Based on aggregated 13F filings for Q1 2025.